Atay Oguzhan sold $1.6M of BLLN

Atay Oguzhan (Chairman and CEO) sold 16,667 shares of BillionToOne, Inc. (BLLN) at an average of $93.79 ($91.57–$96.39, $1.56M total) across 5 trades on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Oct 14, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The complete divestiture by the CEO could be interpreted as a lack of confidence, potentially prompting short‑term selling pressure.

02

Market read

Primary‑source insider sale; modest size but full exit by the CEO may affect short‑term price dynamics.

03

What to watch

The transaction size is modest relative to the company's float and market cap.

Relevance 5/10Novelty 4/10Timing: post‑market

Background

SEC Form 4 filing discloses an insider transaction by the company's chairman and CEO.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

CEO Atay Oguzhan sold all 16,667 shares for $1.56M via a 10b5‑1 plan, leaving zero holdings.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A chief executive exiting his entire position, even via a pre‑arranged plan, is typically viewed as a negative signal for investors.

Market effects

none

none

none

Counterpoint

The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect current sentiment.

Key entities

  • BillionToOne, Inc.

    Issuer of the stock whose CEO sold shares.

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, Inc., the insider seller.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.